CVS Caremark Is Expanding Access and Affordability With Biosimilars
Key Highlights
- ➤CVS Caremark reports approximately $3.3 billion in gross biosimilar savings
- ➤CVS Caremark prefers lower-cost interchangeable biosimilars over Stelara on key formularies
- ➤Nearly half of surveyed employers encourage biosimilar coverage
- ➤Another 40% of surveyed employers are considering or exploring biosimilar coverage
- ➤Forty-three percent cite specialty drug access when choosing a PBM partner
WOONSOCKET, RI / ACCESS Newswire / November 10, 2026 / CVS Health
Key points * Biosimilars can expand access to lower-cost treatments while maintaining the same standards for safety, effectiveness and quality as their reference biologics * Employer interest in biosimilars is growing, with nearly half of surveyed employers encouraging coverage for biosimilars and another 40% considering or exploring it * CVS Caremark is accelerating biosimilar adoption to help improve affordability and access, with its approach delivering approximately $1.5 billion in gross savings for clients and members while maintaining access to treatment As health care leaders work to expand access and improve affordability, biosimilars are creating new opportunities to help patients access the treatments they need. By increasing competition and expanding treatment options, biosimilars are helping to make high-quality care more accessible across the health care system.
Get started
Create a free account to read the full story.